As can be seen in Table 2, patients with earlier stages of PCa showed higher levels of PSMA expression in comparison to patients with CRPC before [177Lu]Lu-PSMA-617 treatment, with significantly different values for SUVmean and SUVmax in the thyroid (both p < 0.001), submandibular glands (p = 0.004; p = 0.013), heart (both p < 0.001), liver (both p < 0.001), pancreas (both p < 0.001), kidneys (both p < 0.001), small intestine (p = 0.006; p = 0.002), testes (both p < 0.001) and bone marrow (p = 0.002; p = 0.002). This evidence concerns the gene FOLH1 and posterior cortical atrophy.